What is EyeCyte?
EyeCyte specializes in advanced amniotic membrane therapies designed to treat a range of ocular conditions, including chronic dry eye, corneal injuries, and eye infections. The company serves both consumers and healthcare providers, offering innovative solutions and educational resources in ocular health. Through its eye doctor finder service, EyeCyte also facilitates patient-provider connections. The company's commitment to regenerative medicine and research positions it as a key player in advancing ocular healthcare.
How much funding has EyeCyte raised?
EyeCyte has raised a total of $3M across 1 funding round:
Series A
$3M
Series A (2008): $3M with participation from Pfizer
Key Investors in EyeCyte
Pfizer
Pfizer is a global biopharmaceutical giant focused on researching, developing, manufacturing, and marketing medicines and vaccines across various therapeutic areas, including oncology and immunology.
What's next for EyeCyte?
The recent major strategic investment indicates a pivotal growth phase for EyeCyte, likely aimed at scaling its therapeutic offerings and expanding its market reach. This enterprise-level funding suggests a focus on further research and development, potentially exploring new applications for its regenerative medicine technologies. The company is well-positioned to solidify its presence in the competitive ocular health market, leveraging this capital to drive innovation and enhance patient care.
See full EyeCyte company page
